US FDA warns Pfizer over tardy pharmacovigilance

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2010年 / 1306卷 / 1期

关键词：

Public Health; Legal Action; Chief Executive; Potential Side Effect; Timely Fashion;

D O I：

10.2165/00128415-201013060-00005

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[1] FDA warns against filling US prescriptions abroad
Reactions Weekly, 2006, 1086 (1) : 3 - 3
[2] FDA warns companies over unapproved chelation products
Reactions Weekly, 2010, 1324 (1) : 2 - 2
[3] US FDA warns of injection-site reactions with naltrexone
Reactions Weekly, 2008, 1216 (1) : 5 - 5
[4] Brazilian diet pills may be harmful, warns US FDA
Reactions Weekly, 2006, 1085 (1) : 3 - 3
[5] US FDA warns companies to stop distributing unapproved prescription narcotics
Reactions Weekly, 2009, 1247-1248 (1) : 3 - 3
[6] FDA warns of asenapine hypersensitivity
Reactions Weekly, 2011, 1368 (1) : 2 - 2
[7] PPIs linked to hypomagnesaemia warns FDA
Reactions Weekly, 2011, 1342 (1) : 2 - 2
[8] FDA warns Revlimid linked to new malignancies
Reactions Weekly, 2011, 1347 (1) : 5 - 5
[9] At the request of the US FDA, Pfizer has suspended its osteoarthritis (OA) clinical programme for tanezumab.
Reactions Weekly, 2010, 1308 (1) : 3 - 3
[10] FDA warns of interaction between vaginal miconazole and warfarin
Reactions Weekly, 2001, 842 (1) : 3 - 3

← 1 2 3 4 5 →